BETRIXABAN

US Previously Marketed

First approved in 2017

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H22ClN5O3
Molecular Weight	451.905
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(C(=O)NC2=CC=C(Cl)C=N2)=C(NC(=O)C3=CC=C(C=C3)C(=N)N(C)C)C=C1

InChI

InChIKey=XHOLNRLADUSQLD-UHFFFAOYSA-N

InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24344662

Betrixaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. Betrixaban is now being developed by Portola Pharmaceuticals. Oral, once-daily Factor Xa inhibitor anticoagulant that directly inhibits the activity of Factor Xa, an important validated target in the blood coagulation pathway, to prevent life-threatening thrombosis. U.S. Food and Drug Administration granted Fast Track designation to betrixaban for extended-duration prevention of venous thromboembolism (VTE; blood clots) in acute medically ill patients (i.e., those who are hospitalized for serious medical conditions, such as heart failure, stroke, infection and pulmonary disease). Has the potential to become the first oral Factor Xa inhibitor anticoagulant approved for hospital-to-home prevention of VTE in acute medically ill patients.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Coagulation factor X 20 Target ID: CHEMBL244 Sources: https://www.portola.com/clinical-development/betrixaban-fxa-inhibitor/ \| https://www.ncbi.nlm.nih.gov/pubmed/24344662	Inhibitor 8297		4.5 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
venous thromboembolism 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf	Preventing		Approved 8429	BEVYXXA Approved Use BEVYXXA is indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. Launch Date 2017
Venous thromboembolism 12 Sources: https://clinicaltrials.gov/ct2/show/NCT01583218	Preventing		Phase III 656	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
23.2 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
73.1 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	80 mg 2 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
122 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	120 mg 2 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
38 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
58.2 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
9.37 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Analyte	Population
179 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
488 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	80 mg 2 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
821 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	120 mg 2 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
393 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
600 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
83.1 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

T_1/2

Value	Dose	Analyte	Population
39.7 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
37.3 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	80 mg 2 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
35.9 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	120 mg 2 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
40% REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		BETRIXABAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
550 mg 1 times / day single, oral Highest studied dose Dose: 550 mg, 1 times / day Route: oral Route: single Dose: 550 mg, 1 times / day Sources: https://www.ema.europa.eu/en/documents/assessment-report/dexxience-epar-refusal-public-assessment-report_.pdf Page: dexxience-epar-refusal-public-assessment-report_.pdf - p.50	healthy, adult n = 59 Health Status: healthy Age Group: adult Sex: M Population Size: 59 Sources: https://www.ema.europa.eu/en/documents/assessment-report/dexxience-epar-refusal-public-assessment-report_.pdf Page: dexxience-epar-refusal-public-assessment-report_.pdf - p.50	Other AEs: Electrocardiogram QTc interval prolonged... Other AEs: Electrocardiogram QTc interval prolonged (grade 1, 3.4%) Sources: https://www.ema.europa.eu/en/documents/assessment-report/dexxience-epar-refusal-public-assessment-report_.pdf Page: dexxience-epar-refusal-public-assessment-report_.pdf - p.50
360 mg 1 times / day single, oral MTD Dose: 360 mg, 1 times / day Route: oral Route: single Dose: 360 mg, 1 times / day Sources: https://www.ema.europa.eu/en/documents/assessment-report/dexxience-epar-refusal-public-assessment-report_.pdf Page: dexxience-epar-refusal-public-assessment-report_.pdf - p.50	healthy, adult n = 59 Health Status: healthy Age Group: adult Sex: M Population Size: 59 Sources: https://www.ema.europa.eu/en/documents/assessment-report/dexxience-epar-refusal-public-assessment-report_.pdf Page: dexxience-epar-refusal-public-assessment-report_.pdf - p.50	Sources: https://www.ema.europa.eu/en/documents/assessment-report/dexxience-epar-refusal-public-assessment-report_.pdf Page: dexxience-epar-refusal-public-assessment-report_.pdf - p.50
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29977165/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000MedR.pdf	unhealthy, median age 76.6 years n = 3716 Health Status: unhealthy Condition: Venous thromboembolism Age Group: median age 76.6 years Sex: M+F Population Size: 3716 Sources: https://pubmed.ncbi.nlm.nih.gov/29977165/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000MedR.pdf	Disc. AE: Haemorrhage, Pulmonary embolism... AEs leading to discontinuation/dose reduction: Haemorrhage (2.4%) Pulmonary embolism Thrombosis venous deep Sources: https://pubmed.ncbi.nlm.nih.gov/29977165/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000MedR.pdf
80 mg 1 times / day steady, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: steady Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 208383Orig1s000MedR.pdf - p.76	unhealthy, median age 76.6 years n = 3716 Health Status: unhealthy Condition: Venous thromboembolism Age Group: median age 76.6 years Sex: M+F Population Size: 3716 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 208383Orig1s000MedR.pdf - p.76	Other AEs: Gastrointestinal bleeding, Intracranial hemorrhage... Other AEs: Gastrointestinal bleeding (major, 19 patients) Intracranial hemorrhage (major, 2 patients) Bleeding (grade 5, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 208383Orig1s000MedR.pdf - p.76
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf	unknown Health Status: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf	Other AEs: Epidural hematoma, Spinal hematoma... Other AEs: Epidural hematoma Spinal hematoma Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf

AEs

AE	Significance	Dose	Population
Electrocardiogram QTc interval prolonged	grade 1, 3.4%	550 mg 1 times / day single, oral Highest studied dose Dose: 550 mg, 1 times / day Route: oral Route: single Dose: 550 mg, 1 times / day Sources: https://www.ema.europa.eu/en/documents/assessment-report/dexxience-epar-refusal-public-assessment-report_.pdf Page: dexxience-epar-refusal-public-assessment-report_.pdf - p.50	healthy, adult n = 59 Health Status: healthy Age Group: adult Sex: M Population Size: 59 Sources: https://www.ema.europa.eu/en/documents/assessment-report/dexxience-epar-refusal-public-assessment-report_.pdf Page: dexxience-epar-refusal-public-assessment-report_.pdf - p.50
Haemorrhage	2.4% Disc. AE	80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29977165/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000MedR.pdf	unhealthy, median age 76.6 years n = 3716 Health Status: unhealthy Condition: Venous thromboembolism Age Group: median age 76.6 years Sex: M+F Population Size: 3716 Sources: https://pubmed.ncbi.nlm.nih.gov/29977165/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000MedR.pdf
Pulmonary embolism	Disc. AE	80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29977165/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000MedR.pdf	unhealthy, median age 76.6 years n = 3716 Health Status: unhealthy Condition: Venous thromboembolism Age Group: median age 76.6 years Sex: M+F Population Size: 3716 Sources: https://pubmed.ncbi.nlm.nih.gov/29977165/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000MedR.pdf
Thrombosis venous deep	Disc. AE	80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29977165/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000MedR.pdf	unhealthy, median age 76.6 years n = 3716 Health Status: unhealthy Condition: Venous thromboembolism Age Group: median age 76.6 years Sex: M+F Population Size: 3716 Sources: https://pubmed.ncbi.nlm.nih.gov/29977165/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000MedR.pdf
Bleeding	grade 5, 1 patient	80 mg 1 times / day steady, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: steady Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 208383Orig1s000MedR.pdf - p.76	unhealthy, median age 76.6 years n = 3716 Health Status: unhealthy Condition: Venous thromboembolism Age Group: median age 76.6 years Sex: M+F Population Size: 3716 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 208383Orig1s000MedR.pdf - p.76
Gastrointestinal bleeding	major, 19 patients	80 mg 1 times / day steady, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: steady Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 208383Orig1s000MedR.pdf - p.76	unhealthy, median age 76.6 years n = 3716 Health Status: unhealthy Condition: Venous thromboembolism Age Group: median age 76.6 years Sex: M+F Population Size: 3716 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 208383Orig1s000MedR.pdf - p.76
Intracranial hemorrhage	major, 2 patients	80 mg 1 times / day steady, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: steady Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 208383Orig1s000MedR.pdf - p.76	unhealthy, median age 76.6 years n = 3716 Health Status: unhealthy Condition: Venous thromboembolism Age Group: median age 76.6 years Sex: M+F Population Size: 3716 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 208383Orig1s000MedR.pdf - p.76
Epidural hematoma		Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf	unknown Health Status: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf
Spinal hematoma		Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf	unknown Health Status: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inducer 781	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BCRP 699 MRP2 383 BSEP 402 OAT1 599 OATP1B1 788 OATP1B3 706 CYP1A2 1524 CYP2C19 1478 CYP3A4/5 278 L-type Ca2+ channels 28 P-gp 1461	P-gp 1537 CYP1A1 349 CYP1A2 1054 CYP2B6 664 CYP2C19 991	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
BSEP 403	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 14.0	no
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 15.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 15.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 15.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 15.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 15.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 15.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 15.0	no
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 15.0	no
MRP2 475	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 14.0	no
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 14.0	no
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 14.0	no
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 14.0	no
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf Page: 14.0	yes [IC50 11.6 uM]
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000CrossR.pdf Page: 15.0	yes [IC50 11.6 uM]
L-type Ca2+ channels 30	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000PharmR.pdf Page: 43.0	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A1 349	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 12.0	minor
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 12.0	minor
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 12.0	minor
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 12.0	minor
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 12.0	minor
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 12.0	minor
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 12.0	minor	unlikely Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 12.0
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 8.0	yes	yes (co-administration study) Comment: ketoconazole increased cmax of betrixaban 2.3x, auc 2.3x; verapamil increased cmax of betrixaban 5x, auc 3x;digoxin had no effect on inhibition Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf Page: 8.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000PharmR.pdf Page: 9.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:140421	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:140421
ChemicalBook	CB02500171	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB02500171
MolPort	MolPort-009-682-948	https://www.molport.com/shop/molecule-link/MolPort-009-682-948
ZINC	ZINC000030691754	http://zinc15.docking.org/substances/ZINC000030691754

PubMed

Title	Date	PubMed
New anticoagulants: focus on venous thromboembolism.	2009 Jul	19601856
Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations.	2010	22282691
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.	2010 Dec	21047577
Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.	2010 Dec 14	21144965
Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice.	2010 May 24	20948848
New anticoagulants for the prevention of venous thromboembolism.	2010 May 25	20531960

Patents

Sample Use Guides

In Vivo Use Guide

80 mg PO QD for 35 day + 7 days.

Route of Administration: Oral

In Vitro Use Guide

In a tissue factor-induced thrombin-generation assay, betrixaban, in concentrations ranging between 5 and 25 ng/ml, inhibited thrombin generation to trough and peak levels comparable to those achieved by 2.5 mg of fondaparinux.

Name

Type

Language

BETRIXABAN

Official Name

English

PRT-054021

Code

English

Betrixaban [WHO-DD]

Common Name

English

BETRIXABAN [MI]

Common Name

English

betrixaban [INN]

Common Name

English

N-(5-Chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide

Systematic Name

English

BENZAMIDE, N-(5-CHLORO-2-PYRIDINYL)-2-((4-((DIMETHYLAMINO)IMINOMETHYL)BENZOYL)AMINO)-5-METHOXY-

Systematic Name

English

BETRIXABAN [USAN]

Common Name

English

BETRIXABAN [ORANGE BOOK]

Common Name

English

PRT054021

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C263